WebGemini Therapeutics, Inc. 2024 Stock Option and Incentive Plan (the “2024 Plan”) Gemini Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”) ... that each person whose signature appears below constitutes and appoints Jason Meyenburg, his or her true and lawful attorney-in-fact and agent, with full power of substitution ... Web12 aug. 2024 · Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today reported its financial results for the second quarter ended June 30, 2024 and provided a business update. “The initial results shared in June …
Biotech Gemini Therapeutics sinks 7.6% on first trading day
Web13 nov. 2024 · “We are extremely pleased that these results have supported advancing GEM103 into a Phase 2a study in a genetically-defined AMD population,” said Jason Meyenburg, CEO of Gemini Therapeutics. “Gemini continues to incorporate its insights in genetics and biology to pioneer precision medicines to restore regulation of the … Web28 feb. 2024 · Gemini Therapeutics (NASDAQ: GMTX) has appointed Georges Gemayel as interim President and CEO. Gemayel, who currently serves as Executive Chair of … sevcan ayse
Gemini Therapeutics CEO Jason Meyenburg leaves exechange
Web13 sept. 2024 · Jason Meyenburg Joins Gemini Therapeutics as CEO 2024 Web12 apr. 2024 · Marc will continue to contribute to Gemini in an advisory role. “We extend our gratitude to Dr. Uknis for the pivotal role he played in advancing GEM103 into clinical development and helping transform Gemini into a publicly traded precision medicine company with a promising clinical pipeline,” continued Mr. Meyenburg. About Gemini … Web7 apr. 2024 · Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, has been granted Fast Track designation by the F ... potential to be an important therapeutic option for patients with dry AMD and CFH loss-of- function gene variants,” Jason Meyenburg, CEO of Gemini Therapeutics, said in a company news … the total reward approach